Related Experiment Video

Updated: May 10, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Personalized medicine in Alzheimer's disease and depression

Tatiana Souslova1, Teresa C Marple, A Michael Spiekerman

  • 1Scott & White Healthcare, Department of Clinical Pathology, 2401, South 31st Street, Temple, TX 76508, USA.

Contemporary Clinical Trials
|July 3, 2013
PubMed

Keywords:
5-HTT5-HTTLPR5-Hydroxytryptamine Transporter geneADADNIADRDAAlzheimer's Disease Neuroimaging InitiativeAlzheimer's Disease and Related Disorders AssociationAlzheimer's diseaseAβ40Aβ42CREBCSFCTCVCYP2C19CYP2D6CYP450Coefficient of VariationComputed TomographyCytochrome P450Cytochrome P450 2C19Cytochrome P450 2D6DNADSMDSM-IV-TRDSM-VDeoxyribonucleic AcidDepressionDiagnostic and Statistical Manual of Mental DisordersDiagnostic and Statistical Manual of Mental Disorders—Fifth EditionDiagnostic and Statistical Manual of Mental Disorders—Fourth Edition-Text RevisionELISAEnzyme-Linked Immunosorbent AssayEpigeneticsFDAFK506-binding proteinFKBP5Food and Drug AdministrationGRIAGRIKHPAIL28RAKCNK2MDDScoreMRIMTCMagnetic Resonance ImagingMajor Depressive Disorder ScoreMethylthioninium ChlorideNINCDSNational Institute of Neurological and Communicative Disorders and StrokeP-tau181PPAPLNPETPersonalized medicinePositron Emission TomographyQCQuality ControlRDoCRNAResearch Domain CriteriaRibonucleic AcidSSRISTAR*DSelective Serotonin Reuptake InhibitorSequenced Treatment Alternatives to Relieve DepressionSerotonin-Transporter-Gene-Linked Polymorphic RegionT-tauTau phosphorylated at threonine 181VNTRWHOWorld Health Organizationbeta-amyloid, amino acids 1–40beta-amyloid, amino acids 1–42cAMP response element-binding proteincerebrospinal fluidglutamate receptor, ionotropic, AMPAglutamate receptor, ionotropic, kainatehypothalamic–pituitary–adrenalinterleukin 28 receptor, alpha (interferon, lambda receptor)papilin, proteoglycan-like sulfated glycoproteinpotassium channel, subfamily K, member 2total Tauvariable nucleotide terminal repeat

More Related Videos

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...